Osteoporosis sits awkwardly for remote prescribing: the condition is common, the first-line treatment is a tablet, and yet the diagnosis depends on a scan no telehealth platform can perform. Most operators who get this vertical right stop trying to diagnose it at all and build around monitoring, adherence, and a clear line to secondary care instead.
What counts as osteoporosis in a telehealth remit
A realistic remit covers three things: ongoing prescribing of oral bisphosphonates for patients who already have a diagnosis, calcium and vitamin D supplementation advice, and structured risk discussions for patients who don't have a diagnosis yet but want to know whether they should be worried. It does not cover diagnosing the disease itself.
That distinction matters commercially as much as clinically. A brand that markets itself as a place to "get checked for osteoporosis" is promising something a remote consultation can't deliver, and the superintendent pharmacist signing off the service needs that gap closed before launch, not discovered after a complaint.
Demand for this vertical skews older than most telehealth verticals, and it tends to arrive already medicated: a meaningful share of enquiries come from patients who were started on a bisphosphonate years ago by a GP or a hospital clinic and simply want a less friction-heavy way to keep the repeat prescription going. Building for that patient, rather than for a hypothetical newly-diagnosed one, is usually the quicker path to a working service.
Diagnosis and triage without a DEXA scan
A formal osteoporosis diagnosis requires a DEXA (dual-energy X-ray absorptiometry) bone density scan, and that's an imaging appointment, not something a video consultation can replace. What a remote clinician can do is run a FRAX assessment, the fracture risk calculator referenced in NICE's CG146 guidance and used alongside National Osteoporosis Guideline Group (NOGG) thresholds to decide what happens next.
FRAX takes a structured history rather than a scan: previous fragility fractures, a parental hip fracture, long-term oral steroid use, smoking, heavy alcohol use, early menopause, and low body mass index all feed into the score. The output sorts patients into three practical buckets:
- Low risk: reassurance, lifestyle advice, no treatment
- Intermediate risk: referral for a DEXA scan before any treatment decision
- High risk: treatment can reasonably start without waiting for a scan, per NOGG guidance
- Already diagnosed elsewhere: the telehealth service picks up ongoing prescribing and monitoring
What a remote prescriber can actually offer
Once a diagnosis exists, whether from a GP, a hospital fracture liaison service, or a private DEXA provider, the ongoing care is genuinely telehealth-shaped. Oral bisphosphonates such as alendronic acid (usually weekly) or risedronate are the first-line treatment, and most of the clinical work from that point is adherence support rather than fresh decision-making.
The dosing instructions are unusually strict and poorly followed in practice: tablets taken first thing in the morning, on an empty stomach, with a full glass of water, followed by staying upright for at least 30 minutes and not eating. A remote service that spends real time on this, rather than just handing over a leaflet, tends to see fewer discontinuations and fewer calls about side effects that are really dosing errors.
Calcium and vitamin D supplementation sits alongside the bisphosphonate rather than replacing it, and is usually the easier half of the consultation: dietary intake, sunlight exposure, and whether an over-the-counter combined supplement is sufficient or a higher-strength prescribed version is warranted. None of this needs a scan or a face-to-face examination, which is exactly why it fits a remote pathway so cleanly.
An osteoporosis telehealth service is a monitoring and repeat-prescribing pathway built on a diagnosis made elsewhere. It is not, and should not be marketed as, a way to diagnose the condition.
The safety-netting a remote bisphosphonate service can't skip
The MHRA has issued safety communications on long-term bisphosphonate use covering two specific risks: atypical femoral fractures, which become more likely the longer treatment continues, and osteonecrosis of the jaw, which is why patients are asked to have dental work completed, or at least flagged, before starting. Neither risk is common, but both need to be part of the consent conversation, not a footnote.
NOGG guidance also recommends a treatment review, often called a "drug holiday" discussion, after three to five years on oral bisphosphonates, weighing continued fracture protection against the cumulative risk profile. A telehealth pathway needs this review built into its repeat-prescription cycle rather than left to the patient to request, alongside basic renal function checks before starting and periodically thereafter.
The referral line: injectable therapies and complex cases
Oral bisphosphonates are not the only treatment, and the alternatives sit outside a safe remote remit. Denosumab is given by injection every six months and carries a specific discontinuation risk: stopping it without bridging to another agent can produce a rebound in fracture risk, including multiple vertebral fractures, well above where the patient started. IV zoledronate carries its own infusion-reaction and monitoring requirements.
Patients who fracture while already on treatment, who can't tolerate oral bisphosphonates due to oesophageal problems, or whose bloods suggest a secondary cause such as hyperparathyroidism or malignancy-related bone disease, belong with a fracture liaison service or endocrinology, not in a repeat-prescription queue. Building that handoff clearly, and training support staff to recognise it, protects patients and the prescriber's registration in equal measure.
Stopping denosumab without a planned bridge to another agent doesn't return a patient to their starting risk, it can leave them at a higher one. That is not a decision to make alone, remotely, at the end of a repeat-prescription queue.
Why this vertical sits next to menopause care, not apart from it
Early menopause is one of the stronger entries on the FRAX risk list, which means an osteoporosis pathway overlaps heavily with an existing menopause telehealth service, particularly where HRT history and bone health discussions naturally sit in the same consultation. Long-term steroid use is a shared risk factor with respiratory and inflammatory conditions too, so the triage questions aren't starting from scratch if a brand already runs a chronic-disease vertical such as hypertension monitoring.
Operationally, the repeat-prescription cadence, the annual review trigger, and the adherence check-ins look a lot like any other long-term medicines pathway. Brands that already have a working repeat-prescription cycle can usually extend it to osteoporosis with a new clinical protocol rather than new infrastructure.
Where PExpo fits
PExpo's role here is the regulated dispensing and compliance layer underneath the clinical decision, not the decision itself: a GPhC-registered pharmacy dispensing the prescribed bisphosphonate, a superintendent pharmacist's sign-off on the repeat-prescribing protocol, and the audit trail a CQC-registered consultation service needs behind it. The clinical judgement on FRAX scores, treatment duration, and the referral line stays with the prescriber.
What PExpo removes is the operational weight of standing that up from nothing: dispensing, patient communications, and the infrastructure a clinic needs to add a vertical like this without rebuilding its back office each time.
Osteoporosis telehealth works when it's honest about its own limits: no scan, no diagnosis, and a referral line that gets used rather than quietly avoided. The commercial upside is less about a flashy acquisition funnel and more about retention: patients on long-term bone-protection treatment stay on a repeat-prescription cycle for years, provided the service keeps the dosing support, the periodic review, and the safety-netting consistent rather than treating it as a one-off transaction.
Done that way, it's a natural extension for a clinic already running menopause or chronic-disease pathways, with a dispensing partner handling the operational side and a white-label platform available for brands that want to launch the vertical from scratch.
Frequently asked questions
Can a UK telehealth service diagnose osteoporosis?
No. Diagnosis requires a DEXA bone density scan, which is an imaging appointment, not something a remote consultation can replace. A telehealth service can use the FRAX risk tool to decide who needs a scan and can manage treatment once a diagnosis has been made by a GP, hospital fracture liaison service, or private provider.
What medicines can be prescribed remotely for osteoporosis?
Oral bisphosphonates such as alendronic acid and risedronate are the usual first-line treatment and are well suited to remote prescribing and repeat-dispensing, alongside calcium and vitamin D supplementation. Injectable therapies such as denosumab, and IV treatments such as zoledronate, generally need in-person administration and closer monitoring, so they sit outside a typical remote-only pathway.
When should an osteoporosis telehealth patient be referred to secondary care?
Referral is appropriate for anyone who fractures while already on treatment, can't tolerate oral bisphosphonates, needs an injectable therapy, or whose history suggests a secondary cause of bone loss such as hyperparathyroidism. A fracture liaison service or endocrinology team is better placed to manage these cases than a repeat-prescription pathway, and prescriber discretion applies in every case.
